Ranbaxy

RANBAXY

SUBMITTED BY: CHAITANYA S SALUNKE.

DIV : CORE C.

ROLL NO :049.

RANBAXY

Ranbaxy Laboratories Limited (Ranbaxy) is a research based international pharmaceutical company serving customers in over 150 countries. For more than 50 years, it has been providing high quality, affordable medicines trusted by healthcare professionals and patients across geographies.

Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.

It has ground operations in 43 countries and 16 manufacturing facilities spread across 8 countries. It has also covered all the top 25 pharmaceutical markets of the world and has a robust presence across both developed and emerging markets.

Offering High Quality, Affordable Pharmaceuticals:

Ranbaxy is a vertically integrated company that develops, manufactures and markets Generic, Branded Generic, Value-added and Over-the-Counter (OTC) products, Anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates. It has a large portfolio of over 500 molecules that cover multiple dosage forms including tablets, capsules, injectables, inhalers, ointments, creams and liquids. Their presence extends across therapies and includes Anti-infectives, Cardiovascular, Pain management, Central Nervous System (CNS), Gastrointestinal, Respiratory, Dermatology, Orthopaedics, Nutritionals and Urology. Biotech and Vaccines are two new segments that we have begun investing in. A stronger presence in these areas will add significant depth to the existing product pipeline.

Through their unique hybrid business model involving Daiichi Sankyo, they also introduce innovator products in markets around the world.

Driven by Innovation:

Their continued focus on Research & Development (R&D) has resulted in several regulatory approvals in both developed and emerging markets. They have multiple R&D centres in Gurgaon, Haryana, India with facilities for generic and innovative research. Their scientists have given India its first New Chemical Entity (NCE) that was launched on April 25, 2012. The product, SynriamTM, is a new age cure for Malaria. With a strong focus on research in generics, they are increasingly working on more complex and specialised areas.

Delivering Value:

Their business philosophy, based on delivering value to our stakeholders, constantly inspires our people to innovate, excel and set new global benchmarks. Their multicultural workforce, comprising more than

14,600 employees of over 50 nationalities, gives them the strength to make quality healthcare accessible to people around the world. They remain committed to aggressively pursuing their mission of ‘Enriching lives globally, with quality and affordable pharmaceuticals’.

Mission:

Enriching lives globally, with quality and affordable pharmaceuticals

Values:

1. Achieving customer satisfaction is fundamental to the business2. Provide products and services of the highest quality3. Practice dignity and equity in relationships and provide

opportunities for the people to realise their full potential4. Ensure profitable growth and enhance wealth of the shareholders5. Foster mutually beneficial relations with all the business partners6. Manage the operations with high concern for safety and environment7. Be a responsible corporate citizen

Top Products of Ranbaxy:

Molecule Drug Class

Atorvastatin & Combinations Hypolipidemics

Donepezil Anti-Alzheimer’s

Valacyclovir Anti-Virals

Simvastatin Hypolipidemics

Amoxicillin+Clavulanic Acid Anti-bacterials

Ketorolac Analgesics

Ciprofloxacin & Combinations Anti-bacterials

Imipenem + Cilastatin Anti-bacterials

Loratadine & Combinations Anti-histaminics

Fenofibrate & Combinations Hypolipidemics

Amoxicillin & Combinations Anti-bacterials

Cephalexin Anti-bacterials

Clarithromycin Anti-bacterials

Ambazone Oral Antiseptics

Pantoprazole & Combinations Proton Pump Inhibitor

THERAPIES:

Anti – Infectives

Ranabaxy has a significant presence in the Anti-infectives segment having leadership position in key markets in Penicillins, Cephalosporins, Macrolides, Flouroquniolones, Anti-fungals, Anti-virals, Anti-retrovirals (ARVs) and critical care. Their leading molecules in this segment are Valacyclovir, Amoxicillin + Clavulanic Acid, Ciprofloxacin, Imipenem + Cilasatin and Amoxicillin. Besides India, the other important markets where they have a strong presence in this segment are the US, South Africa, Russia, France, Germany, Romania, Brazil, Poland, Thailand and Malaysia. Penems form an important part of our portfolio. They sell Imipenem + Cilastatin in more than 50 countries. On April 25, 2012, they launched India’s first New Chemical Entity (NCE), SynriamTM, for the treatment of uncomplicated falciparum malaria. It is a fixed dose combination of Arterolane 150 mg and Piperaquine 750 mg.

Cardio –Vascular

Cardiovascular (CVS) ailments are on the rise all over the world due to changing lifestyles. As a result, there is an increasing need for CVS drugs. Ranbaxy has been at the forefront of developing affordable, quality drugs for various CVS ailments like Hyperlipidemia, Hypertension and Diabetes. Strengthening the global leadership in statins, they launched their generic version of the world’s largest selling drug (Atorvastatin) in the US as a First-to-File (FTF) product. Today, Atorvastatin is marketed by us in more than 25 countries worldwide, including the US, India, Canada, Romania, South Africa, Australia and Malaysia. In markets like India, Romania, Russia, South Africa and Malaysia, Ranbaxy is among the leading companies selling Simvastatin, Rosuvastatin, Aspirin, Losartan and Acarbose formulations.

Pain and Muskuloskeletal

Some of their best-selling molecules in the Pain and Musculoskeletal segment are Ketorolac, Diclofenac, Paracetamol and Ibuprofen combinations. They have launched specialised products like Cox 2 inhibitors for Osteoarthritis in several markets and are working on various specialised molecules to cater to this growing segment.

Gastro-intestinal

Gastrointestinal is another significant therapeutic segment for Ranbaxy. Proton pump inhibitor (PPI) drugs for the treatment of ulcers are the leading drug class for them. In PPIs, like Pantoprazole, Rabeprazole, Lansoprazole and Omeprazole, they are leaders in several markets. Besides PPI, they have a strong presence in Ranitidine,H Pylori kits, Papain and digestive enzyme formulations.

Respiratory

There is a growing global population of patients with ailments relating to Chronic Obstructive Pulmonary Disease (COPD), which makes this therapy an important focus area for them. Ranbaxy has a significant presence in this segment, especially in the US, India, Eastern Europe, South Africa and Latin America. Some of our leading products in this segment are Ambazone, Loratadine combinations, Triamcinolone, Montelukast and Fexofenadine.

Central Nervous System (CNS)

Ranbaxy has a wide portfolio of drugs for Central Nervous System (CNS) ailments like Schizophrenia, Epilepsy, Depression, Neuropathic Pain, Alzheimer’s Disease and Parkinson’s. Their leading molecules in CNS are Donepezil, Sertraline, Gabapentin, Pentazocine and Olanzapine.

Anti–Retro Virals

Ranbaxy offers a wide range of World Health Organisation prequalified (WHO PQ) Anti-retroviral (ARV) products that are supplied in more than 100 countries in Africa, Latin America, CIS and Asia. Close to a million patients worldwide use the ARV products as part of the daily treatment regimen. Ranbaxy were among the first generic companies to

offer ARVs to various National AIDS treatment programmes in Africa. Their ARV portfolio comprises Bio-equivalent Anti-retroviral products and Anti-infectives. The products are manufactured at our state-of-the-art facilities that have been approved by WHO PQ and/or stringent regulatory authorities. ARVs are being procured for large treatment programmes by major institutions such as Unicef, Global Fund – Voluntary Pooled Programme (VPP) (through PFSCM), UNITAID/CHAI (Clinton Health Access Initiative), Red Cross IDA, Missionpharma Crown Agents, Population Services International and United Nations Development Programme.

Dermatology :

Ranbaxy has a major focus in Dermatology with a presence across markets, including the US, India and Brazil. They also have a robust franchise in the Corticosteroids, Anti-infectives and Anti-acne segments. Their current portfolio in the US caters to both prescription and consumer driven Over-the-Counter (OTC) markets, the major brands being Ultravate, Kenalog and Lac Hydrin. They have the global licensing rights to market Luliconazole (a

novel Anti-fungal) in 16 markets, including India, Malaysia, Singapore and South Africa.

Over The Counter (OTC) Products:

Towards a Healthier World

Ranbaxy Global Consumer Healthcare (RGCH) is a separate business division through which they develop and market Over-the-Counter (OTC) products in more than 20 countries across Asia, Africa, the Middle East and Europe. This division is one of our fastest growing and offers 15 products, including some top-selling brands that have leadership status in their respective segments. Some of our key OTC brands are Revital, Volini, Faringosept, Aspenter and Chericof.

RGCH commenced its operations in 2002 with the launch of Pepfiz, Gesdyp and Garlic Pearls in the Indian market. The portfolio was strengthened with the addition of Revital. In 2005, Chericof was added to the offering and, in 2007, Volini, a topical analgesic brand, was introduced.

Today, Revital, our flagship brand in the OTC segment, is India’s largest selling Vitamins & Minerals Supplement. It is also among the Top 5 OTC brands of India. Volini is among the fastest growing pain relievers available in India. It is also counted amongst the Top 10 brands in the Indian pharmaceutical market. Some of our other key OTC brands are Revital Woman, Volini Activ and Revitalite.

Providing Innovative Healthcare Solutions

At RGCH, they strive relentlessly to enhance the well-being of consumers by providing innovative healthcare solutions. They follow the model of staying in constant touch with the market through research and responding to its needs through appropriate products.

The division has an aggressive sales and distribution strategy that involves penetrating Class II towns directly and smaller towns through the ‘hub and spoke’ model. They pursue a differentiated sales and distribution strategy of engaging FMCG/OTC distributors for our OTC products. The distribution infrastructure continues to grow, with about 1000+ distributors and sales representatives covering outlets that account for more than 90% of category volumes for all our major OTC brands.

OTC Products

Brand name Generic name Therapeutic segment

REVITAL Ginseng, Vitamins and Minerals

VMS-Vitamins, Minerals and Supplements

REVITAL LIQUID Ginseng, Vitamins and Minerals

VMS-Vitamins, Minerals and Supplements

REVITAL WOMAN Ginseng, Vitamins and Minerals(Specially formulated for women)

VMS-Vitamins, Minerals and Supplements

REVITAL SENIOR Vitamins, Minerals, Ginseng and Isoflavones(Specially formulated for

VMS-Vitamins, Minerals and Supplements

50 years+)

REVITALITE Soy Protein Supplement VMS-Vitamins, Minerals & Supplements

VOLINI GEL Pain relief Gel ANALGESIC-Topical

VOLINI SPRAY Pain relief Spray ANALGESIC-Topical

VOLINI ACTIV GEL

Ayurvedic Pain relief Gel ANALGESIC-Topical

CHERICOF COUGH SYRUP

Complete Cough Syrup for family

CCA-Cough, Cold & Allergy

PEPFIZ Effervescent digestive enzymes

GI-Gastrointestinal

GARLIC PEARLS Garlic oil for all round health

GI-Gastrointestinal

GESDYP Digestive Enzymes GI-Gastrointestinal

OTC Products are Available Across Countries

India Russia Romania Africa

Vitamins & Dietary Supplements

Revital Revital WomanRevital SeniorRevitalite

Vitamins & Dietary Supplements

Revital Garlic PearlsFenules

Heart Health

AspenterAspacardin

Vitamins & Dietary Supplements

Revital Riconia

Pain RelieversVolini Gel & SprayVolini Activ

Pain RelieversBrustan

Vitamins & Dietary supplements

Pain RelieversPainamol

Glubifer Brustan

Gastrointestinal Remedies

PepfizGarlic PearlsGesdyp

GastrointestinalRemedies

Pepfiz

Gastrointestinal Remedies

Furazolidon

Gastrointestinal Remedies

PepfizGestidVomidon

Cough & Cold Remedies

Chericof

Cough & Cold Remedies

Coldact Flu PlusFaringosept

Cough & Cold Remedies

Faringosept

Cough & Cold Remedies

RhinetonChericof

2013 Award

ASSOCHAM Innovation Excellence Platinum Award

Ranbaxy wins the ASSOCHAM Innovation Excellence Platinum Award for SynriamTM, a new age cure for malariaGolden Peacock Award

Ranbaxy wins the Golden Peacock Innovative Product/Service Award for SynriamTM, a new age cure for malaria

2012

Frost & Sullivan Pharmaceutical Company of the Year

Ranbaxy wins the 2012 Frost & Sullivan Malaysia Excellence Award for being adjudged the Malaysian Pharmaceutical Company of the Year in the Generics Drug Category

Best Pharma Company for the year 2011 – Dun & Bradstreet

Ranbaxy is awarded the Best Pharma Company of the Year 2011 by Dun & Bradstreet

2011

Padma Shri, the Fourth Highest Civilian Award in India, for Dr. Nitya Anand, Chairman of Ranbaxy Science Foundation

Dr. Nitya Anand, Chairman of Ranbaxy Science Foundation, is honoured by the President of India with the Padma Shri, the Fourth Highest Civilian Award, in recognition of his notable performance in the field of drug research

The Economic Times IMEA 2011 – Gold Award in the Pharmaceuticals Sector

Ranbaxy wins the Economic Times IMEA 2011 – Gold Award in the Pharmaceuticals Sector. The award is conceptualised and instituted by Frost and Sullivan in collaboration with The Economic Times

New Jersey Business and Industry Association Award for Excellence

Ranbaxy is felicitated with the New Jersey Business and Industry Association Award for Excellence in the Business Expansion Category

Brand of the Year 2011 Award for Revital and Volini

Ranbaxy bags ‘Brand of the Year 2011 Award for Revital and Volini’ at the Pharmaceutical Leadership Awards 2011 organised by Pharma Leaders, India’s leading pharma magazine and the Indo-American Chamber of Commerce

India’s most Admired Nutrition and Neutraceuticals for Revital Woman

Ranbaxy wins Award for the Year 2011 for ‘India’s most Admired Nutrition and Neutraceuticals’ for Revital Woman at the Pharmaceutical Leadership Awards 2011 organised by Pharma Leaders, India’s leading pharma magazine and the Indo-American Chamber of Commerce

Pharma OTC Company of the Year 2011

Ranbaxy is recognised as ‘Pharma OTC Company of the Year 2011′ for its Global Consumer Healthcare Division at the Pharmaceutical Leadership Awards 2011 organised by Pharma Leaders, India’s leading pharma magazine and the Indo-American Chamber of Commerce

CSR Organisation of the Year 2011

Ranbaxy wins the title of ‘CSR Organisation of the Year 2011′ at the Pharmaceutical Leadership Awards 2011 organised by Pharma Leaders, India’s leading pharma magazine and the Indo-American Chamber of Commerce

2010

Best Policy Holder Award

Ranbaxy bags the Best Policy Holder Award in the category of Best Compliance Practices

Reader’s Digest Trusted Brand

Revital is recognised as the ‘Reader’s Digest Trusted Brand’ in the Health & Personal Care (Vitamin/ Health Supplements) category in 2010. Revital receives the exclusive gold award in the category

Nigerian Awards for Roscillox and Gestid

The Institute of Direct Marketing of Nigeria recognises Ranbaxy’s Roscillox suspension as the most effective and preferred antibiotic in its segment. Gestid bags the Excellence Award in the category of Antacid Brand of the Year from the Institute of Brand Management, Nigeria

Samman Patra

Ranbaxy’s plant in Dewas, Madhya Pradesh, India receives the ‘Samman Patra’ for being ranked 2nd in the category for contribution towards service taxThompson Reuters Innovation Award

Ranbaxy is felicitated with the Thompson Reuters Innovation Award, in recognition of being India’s Most Innovative Pharma Corporate Enterprise for the year 2010

No. 1 in the Generics Category

Ranbaxy is ranked No. 1 in the Generics category in improving access to needed medicines in a study in 2010 by Access to Medicine (ATM) foundation, a Netherlands-based non-profit organisation which is an initiative to improve access to medicines worldwide

2009

Outstanding Contribution to the Pharmaceutical Industry

Ranbaxy is recognised for its ‘Outstanding Contribution to the Pharmaceutical Industry’ by Pharmexcil, India

2007

Most Respected Company of the Year

Ranbaxy is ranked No. 1 in the pharma sector in the Most Respected Companies Survey by Business World, India’s leading business magazine

Most Innovative Company of the Year

Ranbaxy is recognised as one of the Most Innovative Companies in a survey by Business Today, a leading business magazine in India

Largest Employer of the Year in the Pharmaceutical Industry

NJBIZ, the leading business publication in New Jersey, recognises Ranbaxy as one of the largest employers in the pharmaceutical industry in the state of New Jersey in the US

Marketing Excellence Award for Volini

Organisation of Pharmaceutical Producers of India (OPPI) selects

Ranbaxy’s leading brand Volini for the Marketing Excellence Award 2007 in the new product category

IPA Bilcare Award for Packaging

Ranbaxy wins the IPA Bilcare Award for its ‘Twin pocket nested pouch’ developed by the R&D Packaging Team

Pharma Excellence Award

Ranbaxy is felicitated with the Pharma Excellence Award for ‘Leveraging Global Opportunity’ by the Express Pharma Group. It is lauded for creating a niche for itself in the most competitive global pharmaceutical industry

2006

Prestigious Private Label Supplier of the Year Award

Ranbaxy’s US subsidiary, Ohm Labs receives the prestigious Private Label Supplier of the Year Award from AmerisourceBergen, one of the world’s largest pharmaceutical services companies serving the US, Canada and other select markets

National Award for Excellence in Water Management

Ranbaxy’s manufacturing plant in Toansa, Punjab, India receives the National Award for Excellence in Water Management 2005 for being an ‘Excellent Water Efficient Unit’

Ranbaxy Russia – Company of the Year Award

Ranbaxy Russia is bestowed with the ‘Profession is Life – Company of the Year Award’ in the category of ‘Manufacture and Promotion of Medical Goods and Services’ in 2006

Most Consistent Wealth Creator

Ranbaxy is honoured in India as the nation’s ‘Most Consistent Wealth Creator’ by Motilal Oswal Securities, for the period 1991-2006. The Annual Wealth Creation Study identifies the top 100 wealth creators amongst companies that have added at least Rs. 1 billion to their market capitalisation during the period 2000-06

Terapia Ranbaxy Awarded European Health 2006 Trophy

Reader’s Digest awards Terapia Ranbaxy the European Health 2006 Trophy for Excellence in Communication

2005

US Subsidiary Receives Supplier Quality Award

Ranbaxy’s US subsidiary receives the Supplier Quality Award from Cardinal Health, the second largest wholesaler in the US

US Subsidiary Receives the Supplier Award from Walmart

Ranbaxy’s US subsidiary receives the prestigious Supplier Award from Walmart, the largest chain store in the US, for outstanding performance in the first quarter of 2005

Amity Global Corporate Excellence Award

Ranbaxy receives the Amity Global Corporate Excellence Award as a recognition of its best practices

Ranbaxy among India’s Best Managed Companies of the year

Ranbaxy is featured in the elite group of India’s Best Managed Companies in a survey conducted by Business Today, the largest-circulated business fortnightly in India

2004

Pharma Pulse Award

Ranbaxy receives ‘Pharma Pulse Award’ for being the best exporter of the year

Yanhcheng Friendship Award

Ranbaxy Guangzhou China Limited wins the Yanhcheng Friendship Award for its contribution to the local economy and the development of the society of Guangzhou, China

National Award for excellence in Energy Management

Ranbaxy’s manufacturing facility in Toansa, Punjab, India wins the National Award for Excellence in Energy Management

Business of the Year Award

Ranbaxy and Ohm Labs bag the prestigious ‘Business of the Year Award’ from Brunswick Chamber of Commerce, US

Indiastar Award

Ranbaxy receives the prestigious Indiastar Award of the Year for Best Packaging

Greentech Environment Excellence Award

Ranbaxy’s plant in Toansa, Punjab, India bags the prestigious ‘Greentech Environment Excellence Silver Award’ in the pharma sector for the year 2003-04. The awards are given away by the Greentech Foundation, a Non Governmental Organisation

Frost & Sullivan Entrepreneurial Company of the Year

Ranbaxy Brazil bags the prestigious Entrepreneurial Company of the Year Award from Frost & Sullivan

Frost & Sullivan Award 2004

Ranbaxy US receives the Frost & Sullivan Award 2004 for Customer Value

2003

ET (The Economic Times) Award

Ranbaxy receives the ‘ET Award for Best Performing Company of the Year’ from The Economic Times, India’s largest business newspaper

Best Exporter Award

Ranbaxy bags the CONCOR (Container Corporation of India) Best Exporter Award for the year 2002-03 in the air exports category

Top Products of RanbaxyMolecule Drug Class

Atorvastatin & Combinations Hypolipidemics

Donepezil Anti-Alzheimer’s

Valacyclovir Anti-Virals

Simvastatin Hypolipidemics

GDP% average annual GDP growth

1900 – 1950 1.0

1950 – 1980 3.5

1980 – 2002 6.0

2002 – 2006 8.0

2002-2012 UPTO 8.1

COMPARISON OF RANBAXY WITH OTHER COMPANIES

CONCLUSION

With a couple of sentences, I would like to address you that Ranbaxy Pharmaceutical Company is growing on a larger scale. It has many benefits and profits which will be coming in the future years.

Therefore, I would like to conclude that I thoroughly enjoyed working on this company as my assignment.